Israel Peptic Ulcer Treatment Market By Product Type (Proton Pump Inhibitors, H2 Antagonists, Antibiotics, Others), By Disease Indication (Gastritis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD), By End User (Hospital Pharmacies,

Israel Peptic Ulcer Treatment Market By Product Type (Proton Pump Inhibitors, H2 Antagonists, Antibiotics, Others), By Disease Indication (Gastritis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD), By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2028F

Israel peptic ulcer treatment market is expected to grow at an impressive rate during the forecast period, 2024-2028. The major factors include increasing prevalence of peptic ulcer diseases, rising R&D activities and strong pipeline of new drugs, and increasing investment for healthcare infrastructure. Also, the awareness is rising for minimally invasive procedures for the treatment of peptic ulcers, which, in turn, is expected to promote the growth of the Israel peptic ulcer treatment market during the forecast period. According to National Institute of Health, National Center for Biotechnology Information, Children in Israel have a high prevalence and early acquisition of Helicobacter pylori (H. pylori) that causes an infection in the stomach or duodenum (first part of the small intestine) to further develop the peptic ulcer.

Peptic ulcers are sores in the lining of the stomach, lower esophagus, or small intestine caused by inflammation from the bacteria Helicobacter pylori (H. pylori) and stomach acid erosion. Peptic ulcers are generally caused owing to radiation therapy, inflammation, and frequent use of aspirins parentally or orally. Untreated peptic ulcers can lead to the complications such as severe pain in upper or mid-body parts, severe blood loss, internal bleeding, and weight loss, which may need instant hospitalization. The Israel peptic ulcer treatment market is a growing market as the prevalence of peptic ulcer disease increases due to factors such as stress, unhealthy diets, and increased use of nonsteroidal anti-inflammatory drugs (NSAIDs).

Additionally, the rise in awareness related to complications associated with peptic ulcer disease is a major factor that fuels the growth of the Israel peptic ulcer treatment market. Moreover, increase in geriatric population and sedentary lifestyle boost the growth of the market. However, recent patent expirations are anticipated to hinder the growth of the Israel peptic ulcer treatment market.

Increasing Prevalence of Peptic Ulcer Diseases

One of the primary drivers of the Israel peptic ulcer treatment market is the increasing prevalence of peptic ulcer disease. This condition is becoming more common nowadays, with an estimated 10% of the overall population affected. This is due to various factors such as stress, unhealthy diets, and increased use of nonsteroidal anti-inflammatory drugs (NSAIDs), which can contribute to the growth of the Israel peptic ulcer treatment market.

Israel has one of the highest rates of peptic ulcer disease in the world, with an estimated 10%-15% of the population affected. This high prevalence has created a significant demand for effective treatments, which has led to the introduction of new drugs in the market. In Israel, drugs such as proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), and antibiotics are commonly used to treat peptic ulcers, and pharmaceutical companies are investing in research and development of new and improved drugs for this condition. The increasing prevalence of peptic ulcer disease in Israel has also encouraged the adoption of advanced diagnostic and treatment technologies, such as endoscopy and laser treatment. These technologies allow for early detection and treatment of peptic ulcers, which can improve patient outcomes and reduce healthcare costs. The high prevalence of peptic ulcer disease in Israel has also led to the development of advanced research centers, which are focused on the study of peptic ulcers and the development of new treatments. These centers are staffed by leading experts in the field of gastroenterology, and they collaborate with pharmaceutical companies to develop new drugs and treatment methods. Therefore, peptic ulcers promote the development of new and innovative drugs and encourage the adoption of advanced diagnostic and treatment technologies. These factors are expected to continue driving the growth of Israel peptic ulcer treatment market in the coming years.

Rising Number of R&D Activities and Strong Pipeline of New Drugs

The growing number of peptic ulcer patients is motivating the key players present in the market to invest in the research/development activities. This can positive impact the growth of the Israel peptic ulcer treatment market. For instance, a company namely RedHill Biopharma Ltd. received the United States Food & Drug Administration (USFDA) approval for RHB-105(Talicia) to treat Helicobacter pylori in adults in the US in March 2020.

Strong market players are using their long-term strategies to acquire a competitive advantage such as new product launches, collaboration partnerships, and upgradation of products. Moreover, rising government investment for the development of advanced technologies will further provide beneficial opportunities for the market during the forecast period.

Several clinical trials are going on for most of the drugs to overcome the complications related to currently available drugs. This is another factor which is likely to fuel the growth of the Israel peptic ulcer treatment market during the forecast period. For instance, according to the clinicaltrials.gov, a company namely Takeda Pharmaceuticals has a drug Vonoprazan fumarate in phase 3 trials, which is a drug of category potassium competitive acid blockers (P-CABs) for peptic ulcer treatment market. Additionally, GlaxoSmithKline plc is another major player in the Israel peptic ulcer treatment market. The company is focused on developing new therapies for peptic ulcer treatment that target the underlying causes of the disease. GlaxoSmithKline has several drug candidates in its pipeline, including GSK-2330672, a novel H2 blocker that has shown promising results in early clinical trials.

AstraZeneca is a leading pharmaceutical company that is investing heavily in R&D to develop new treatments for peptic ulcers. The company has several drug candidates in its pipeline, including AZD-3342, a selective gastrin receptor antagonist that is being developed for the growth of the Israel peptic ulcer treatment market. The company is also investigating the use of combination therapies to improve the efficacy of Israel peptic ulcer treatment market.

Increasing Investment for Healthcare Infrastructure

Another significant factor influencing the growth rate of the Israel peptic ulcers market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the Israel peptic ulcers market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction to smoking will result in the expansion of the Israel peptic ulcer market. The rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period.

The public health campaigns have also played a role in increasing awareness of the health risks associated with peptic ulcers in Israel. These campaigns aim to educate the public about the importance of healthy lifestyle choices, such as diet and exercise, in preventing hypertension. They also encourage people to get their blood pressure checked regularly and to seek medical treatment for the sores present in the inner lining of the stomach. In addition to public health campaigns, educational programs and outreach initiatives have been implemented to induce awareness regarding peptic ulcer diseases and its treatment in Israel. These factors and programs give rise to the growth of the Israel peptic ulcer treatment market.

Market Segmentation

The Israel peptic ulcer treatment market can be segmented by product type, disease indication, end user, and region. By product type, the market can be segmented into proton pump inhibitors, H2 antagonists, antibiotics, and others. Based on disease indication, the market can be segmented into gastritis, gastric ulcer, duodenal ulcer, and gastroesophageal reflux disease (GERD). In terms of end users, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Market Players

Pfizer Pharmaceuticals Israel Ltd, AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, GlaxoSmithKline (Israel) Ltd, Takeda Israel Ltd., Israel B. Abbott., and Phibro Israel are some of the leading companies operating in the Israel Peptic Ulcer Treatment Market.

Report Scope:

In this report, the Israel peptic ulcer treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Israel Peptic Ulcer Treatment Market, By Product Type
• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Others
• Israel Peptic Ulcer Treatment Market, By Disease Indication
• Gastitis, Gastric Ulcer
• Duodenal Ulcer
• Gastroesophageal Reflux Disease (GERD)
• Israel Peptic Ulcer Treatment Market, By End User
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Israel Peptic Ulcer Treatment Market, By Region:
• The Mediterranean coastal plain
• The Central Hills
• The Jordan Rift Valley
• The Negev Desert

Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Israel peptic ulcer treatment market.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights